The combination targets two complementary mechanisms in MTAP-deletion solid tumors, offering a potential first-in-class treatment option

MTAP-deletion prevalence in NSCLC is estimated to be around 15%, representing a significant patient population

The collaboration expands an ongoing Phase 1 trial, which previously focused on evaluating the combination in MTAP-deletion urothelial cancer

Both companies retain commercial rights to their respective drugs, with IDEAYA sponsoring the study and Gilead providing Trodelvy